IL10 and graft versus host disease: In 4 out of 12 patients with hemoblastoses, after the introduction of alloantigen-specific donor IL-10-anergized T cells (IL10-DLI) containing Tr1 (on average 35 days after haplo-HSCT), GVHD did not develop, and disease remission was maintained for a long time [90].